Swiss drugmaker Novartis (NOVN.S), opens new tab and drug developer Monte Rosa Therapeutics (GLUE.O), opens new tab signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion. Shares of Monte Rosa surged 65% in premarket trading after the announcement. Immune-mediated diseases occur when the immune system mistakenly attacks healthy tissues, causing inflammation and damage. These hard-to-treat conditions significantly impact patients' quality of life. The deal grants Novartis exclusive rights to an undisclosed drug‑discovery target and options to license two additional programmes from Monte Rosa’s early‑stage immunology portfolio. Monte Rosa Therapeutics will utilize its AI-enabled platform to discover and develop new degraders - small molecules designed to break down disease-causing proteins - which Novartis will then take forward into clinical development and commercialization.
شركات
مواضيع مرتبطة
شركات
إكس أس دوت كوم" تعزز ريادتها في المنطقة العربية بتعيين عمر علاء مديراً إقليمياً للتسويق
الأربعاء 10 يونيو 2026
شركات
الصين تندد بإدراج "علي بابا" و"بايدو" على القائمة السوداء الأميركية وتلوح بإجراءات مضادة
الثلاثاء 09 يونيو 2026التعليقات
